Proceeds from our Rock the Cure events ($105,000) have been used to explore exciting approaches to generate individualized vaccines for kidney cancer patients. The approach will use fresh biopsies from kidney cancer patients to accurately represent their current cancer immune profile. The cells are then cultured and multiplied using a novel cell culture technique and can serve in the future as the basis for a patient specific whole cell or RNA vaccine. The advantage of this approach is that it not only directs the immune system to the specific mutations of the tumor, but also other over expressed common and rare normal proteins and activated retroviruses. Thus, the full repertoire of targets for the immune system will be displayed. While vaccines in the past have been met with moderate benefit at best, they are now poised to synergize with the modern immunotherapy revolution of immune checkpoint inhibitors.
My death sentence was commuted by something called RADVAX — a clinical trial in its second phase being run by Dr. Hans Hammers, a recent Johns Hopkins transplant to UT Southwestern. The trial is being funded by KidneyCAN.
KidneyCAN had a successful day on the Hill, October 21-22, 2019 advocating for kidney cancer research. Advocates from GA, PA, MI, DC, MA, NY, MD, LA, NJ, VA, TX and WI showed up to let their voice be heard for continued research funding. If your state was not represented, PLEASE consider attending our next advocacy day Spring 2020.
In the News
Funded major projects to date include:
RADVAX investigator led immunotherapy trial for 25 advanced kidney cancer patients at UT Southwestern combining Nivolumab, Ipilimumab and SBRT.
Support of UT Southwestern’s Kidney Cancer Research Program. 1 of only 2 SPOREs (Specialized Programs of Research Excellence) for Kidney Cancer in the US.
Our primary sources of support are donations from the general public and fundraising.
Please enter your information below: